$CYRX

CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares

CryoPort's CFO, Robert Stefanovich, recently sold 2,743 shares of the company's stock for $8.00 per share, totaling $21,944, reducing his holdings by 0.97%. This follows a previous sale of 38,700 shares on March 12th. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with a target price of $12.94.

Original reporting
MarketBeat · MarketBeat
Published Mar 17, 2026, 2:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 17, 2026, 3:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares — source image
Decision brief

The 30-second read

$CYRXNeutralLow
01

Why it matters

The insider sale at $8.00 per share, below the analyst target price of $12.94, suggests that insiders may be taking profits rather than signaling a decline in company prospects.

02

Market read

The insider activity is relevant but not alarming; it should be considered alongside other fundamental and technical factors.

03

What to watch

Lack of information on the company's current financial health, upcoming catalysts, or broader market conditions limits the analysis.

Timing: short-term

Background

CryoPort is a provider of temperature-controlled logistics solutions, with insider trading activity being one of many factors influencing its stock.

Company-level read

Ticker impact

$CYRXNeutralMedium confidence
Context

The news involves the company's CFO selling shares, which can be a sign of insider sentiment but is not necessarily indicative of the company's fundamental outlook.

Expected impact

Limited immediate impact; potential slight bearish bias if viewed as insider profit-taking, but overall effect is minimal.

Evidence & confidence

Insider sales can be routine or strategic; without additional context, the impact on stock price is uncertain.

$CYRXNeutralMedium confidence
Context

The news is directly related to the company's insider trading activity, which can influence investor perception.

Expected impact

Likely negligible; no significant price movement expected based solely on this activity.

Evidence & confidence

Insider sales are one data point; other factors like financial performance and market conditions are more influential.

Market effects

The sale is specific to CryoPort and does not indicate sector-wide issues.

Minimal; the activity is company-specific and unlikely to affect regional markets.

Negligible; the news has limited global market implications.

Counterpoint

Insider sales could be routine and not indicative of future performance; some investors may view this as a normal portfolio rebalancing.

Key entities

  • Robert Stefanovich

    Chief Financial Officer of CryoPort, involved in recent share sales.

  • CryoPort

    Provider of temperature-controlled logistics solutions, NASDAQ: CYRX.

Related articles

$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

$CYRXMed

Cryoport, Inc. (CYRX): Results of Operations and Financial Condition

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

$VLOMed

Morgan Stanley Sees More Fuel for Valero’s (VLO) Rally

Valero Energy (VLO) has gained 140% in 2026 due to high refining margins. Morgan Stanley raised its price target to $411, citing strong earnings and cash flows. VLO's Q2 profit was record-high, and it returned $2.6B to shareholders. Concerns include potential declines in refining margins and sustainability of shareholder returns.

$MPCMed

Marathon Petroleum (MPC) Could Smash its All-Time High, UBS Says

Marathon Petroleum (MPC) stock has more than doubled in 2026, nearing all-time highs due to tight global refining supplies. UBS raised its price target to $450, citing strong refining margins and high shareholder returns. MPC's Q2 profits quadrupled, but risks include potential margin declines and operational challenges. Hedge funds increased holdings in MPC during Q2 2026.